Platform Leaders
Companies with established bioprinting platforms and commercial products
CELLINK
Market-leading bioprinting hardware and bioinks. BIO X series printers. Part of Bico Group. Global bioprinting ecosystem.
Organovo
3D bioprinting pioneer. ExVive liver and kidney tissues. Now focused on therapeutics pipeline. OTC: ONVO.
Aspect Biosystems
Microfluidic 3D bioprinting. Lab-on-a-Printer technology. J&J partnership for diabetes. $140M+ raised.
3D Systems Healthcare
Medical 3D printing with bioprinting applications. Print to Perfusion platform. NYSE: DDD.
Light-Based & Volumetric Bioprinting
Next-generation bioprinting using light-based polymerization
Readily3D
Tomographic volumetric bioprinting. EPFL spinout. Sub-second printing of complex structures.
Volumetric Inc
Rapid light-based bioprinting. Rice University and UT spinout. Focused on vascularized tissues.
UpNano
Two-photon polymerization for micro-scale bioprinting. Austrian precision engineering. NanoOne Bio printer.
Poietis
Laser-assisted bioprinting. French biotech. Skin bioprinting for L'Oréal and BASF.
Bioink & Biomaterial Specialists
Companies developing specialized materials for bioprinting
Advanced BioMatrix
Collagen-based bioinks and ECM products. LifeInk portfolio. San Diego-based materials company.
Allevi (3D Systems)
Desktop bioprinters and bioinks. Acquired by 3D Systems 2021. Democratizing bioprinting.
Gelomics
GelMA and hydrogel bioinks. Australian materials company. Focus on reproducibility.
Manchester BIOGEL
PeptiGel synthetic hydrogels. University of Manchester spinout. Peptide-based bioinks.
Therapeutic Bioprinting
Companies developing bioprinted tissues for transplantation and regenerative medicine
LyGenesis
Cell therapy for liver regeneration. Lymph node-based organ growth. Phase 2 clinical trials.
Trestle Biotherapeutics
Bioengineered kidney tissue. UCSD spinout. Implantable renal tissue patches.
Pandorum Technologies
3D bioprinted corneas. Indian biotech. First bioprinted cornea implants in clinical trials.
BIOLIFE4D
Bioprinted cardiac patches. Chicago-based. Patient-specific heart tissue development.
Sector Analysis
Market Overview
- + 3D bioprinting market projected to reach $3.3B by 2030 (18% CAGR)
- + Bico Group consolidation creating industry ecosystem
- + First bioprinted tissue therapies entering clinical trials
- + Drug discovery applications driving near-term revenue
- + Convergence with organ-on-chip and organoid technologies
Explore More Categories
Discover companies across all human-relevant technology sectors